1 |
An D , Kewalramani G, Chan JK Y et al (2006). Diabetologia, 49, 2174-84.
DOI
|
2 |
Avila MA, Berasain C, Sangro B, et al (2006). New therapies for hepatocellular carcinoma. Oncogene, 25, 3866-84.
DOI
|
3 |
Bailey CJ, Turner RC (1996). Metformin. N Engl J Med, 334, 574-9.
DOI
ScienceOn
|
4 |
Bolster DR, Crozier SJ, Kimball SR, et al (2002). AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through downregulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem, 277, 977-80.
|
5 |
Bowker SL, Majumdar SR, Veugelers P et al (2006). Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 29, 254-8.
DOI
ScienceOn
|
6 |
Buzzai M, Jones RG, Amaravadi RK (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res, 67, 6745-52.
DOI
|
7 |
Cantrell LA, Zhou C, Mendivil A, et al (2010). Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecologic Oncology, 116, 92-8.
DOI
|
8 |
Currie CJ, Poole CD, Gale EA (2009). The influence of glucose-lowering therapie on cancer risk in type 2 diabetes. Diabetologia, 52, 1766-77.
DOI
|
9 |
Daniels D, Grytdal S, Wasley A (2009). Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ, 58, 1-27.
|
10 |
Dowling RJO, Zakikhani M, Fantus IG, et al (2007). Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res, 67, 10804-12.
DOI
ScienceOn
|
11 |
Duncan B, Schmidt MI (2009). Metformin, cancer, alphabet soup, and the role of epidemiology in etiologic research. Diabetes Care, 32, 1748-50.
DOI
|
12 |
Evans JM, Donnelly LA, Emslie-Smith AM, et al (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5.
DOI
|
13 |
Goodwin PJ, Stambolic V, Lemieux J, et al (2011). Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat, 126, 215-20.
DOI
|
14 |
Gotlieb WH, Saumet J, Beauchamp MC (2008). In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic Oncology, 110, 246-50.
DOI
|
15 |
Hidalgo M, Rowinsky EK (2000). The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19, 6680-6.
DOI
|
16 |
Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res, 69, 7507-11.
DOI
|
17 |
Kalender A, Selvaraj A, Kim SY, et al (2010). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab, 11, 390-401.
DOI
|
18 |
Holland EC, Sonenberg N, Pandolfi PP, et al (2004). Signaling control of mRNA translation in cancer pathogenesis. Oncogene, 23, 3138-44.
DOI
|
19 |
Huang X, Wullschleger S, Shpiro N, et al (2008). Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J, 412, 211-21.
DOI
|
20 |
Kahn BB, Alquier T, Carling D, et al (2005). AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 1, 15-25.
DOI
ScienceOn
|
21 |
Lee MS, Hsu CC, Wahlqvist M, et al (2011). Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer, 11, 20.
DOI
|
22 |
Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5.
DOI
|
23 |
Li DH, Ching JS, Yeung M, et al (2009). Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 137, 482-8.
DOI
|
24 |
Sahra IB, Laurent K, Loubat A, et al (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-86.
DOI
ScienceOn
|
25 |
Wright JL, Stanford JL (2009). Metformin use and prostate cancer in Caucasian men: Results from a population-based case-control study. Cancer Causes Control, 20, 1617-22.
DOI
|
26 |
Schneider MB, Matsuzaki H, Haorah J, et al (2001). Prenvention of pancreatic cancer induction in hamsters by metformin. Gastroenterology, 120, 1263-70.
DOI
|
27 |
Soranna D, Scotti L, Zambon A (2012). Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis. The Oncologist, 17, 1083-7159.
|
28 |
Wang LW, Li ZS, Zou DW, et al (2008). Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol, 14, 7192-8.
DOI
|
29 |
Wullschleger S, Loewith R, Hall MN (2006). TOR signaling in growth and metabolism. Cell, 124, 471-84.
DOI
ScienceOn
|
30 |
Yu Y, Sato JD (1999). MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol, 178, 235-46.
DOI
ScienceOn
|
31 |
Zakikhani M, Dowling R, Fantus IG, et al (2006). Metformin Is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells. Cancer Res, 66, 10269-73.
DOI
|
32 |
Zhu Z, Jiang W, Thompson MD, et al (2011). Metformin as an energy restriction mimetic agent for breast cancer prevention. J Carcinog, 10, 17.
DOI
|